Study design and data source
We retrospectively monitored hospitalized patients with drug recordings from May 1, 2022, to April 30, 2023. We used muscle adverse reaction module in ADE-ASAS-Ⅱ to extract electronic medical record (EMR). If EMR satisfied, warning signals would be given for clinical pharmacists to determine positive cases or not. If patients had multiple positive signals during hospitalization, only the first signal was assessed.